Analyst Sees Significant Upside for Eli Lilly Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: NASDAQ.COM
- Market Leadership: Eli Lilly's dominant position in the weight-loss drug market positions it well for a bright outlook, with analysts projecting significant growth in this sector over the next decade, which is expected to drive solid medium-term growth for the company.
- Sales Growth Potential: Analysts predict that Eli Lilly's weight-loss portfolio, including the newly launched Foundayo and Zepbound, could generate approximately $31 billion in sales in the U.S. next year, potentially rising to $45 billion by 2030, indicating strong revenue growth potential.
- Competitive Risks: Despite facing pressure from competitors, particularly with CVS Health's decision to drop coverage for Zepbound in favor of the cheaper Wegovy, analysts still believe that the company's robust R&D pipeline in weight-loss drugs provides a competitive edge.
- Diversified Pipeline: Eli Lilly's extensive R&D pipeline in oncology and neuroscience, combined with its strong performance in the weight-loss market, may enhance the company's resilience against competition, further solidifying its market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 851.210
Low
950.00
Averages
1192
High
1500
Current: 851.210
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LILLY Q1 ADJUSTED EPS REACHES USD 8.55, BEATING IBES ESTIMATE OF USD 6.66
Economic Adjustments: The report indicates an adjusted earnings per share (EPS) of $8.55, reflecting a positive outlook for the company.
Comparison with Estimates: This adjusted EPS surpasses the estimated EPS of $6.66, suggesting stronger-than-expected financial performance.
See More
Eli Lilly Q1 Earnings Forecast
- Earnings Release Date: Eli Lilly & Co. is set to announce its Q1 earnings on April 30, which is highly anticipated by the market and expected to provide insights into the company's latest developments in drug research and market performance.
- Earnings Per Share Expectation: Analysts forecast that Eli Lilly's Q1 earnings per share will reach $6.79, a significant increase from $3.34 in the same period last year, indicating a robust recovery in drug sales and market demand.
- Stock Price Movement: Despite the optimistic outlook for the earnings report, Eli Lilly's stock fell by 2.6% on Wednesday, likely influenced by overall market sentiment and profit-taking by investors, reflecting short-term market uncertainties.
- Market Reaction Analysis: Analysts maintain a cautiously optimistic view on the upcoming earnings report, anticipating that strong earnings growth will provide funding for future investments and research, thereby enhancing the company's competitive position in the pharmaceutical industry.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
Strong Earnings Reports from Top Tech Giants
- Alphabet's Strong Performance: Alphabet's earnings report exceeded expectations with strong performance in search, subscriptions, and cloud services, leading to an 8% stock increase and reflecting significant returns on AI investments, boosting market confidence.
- Amazon's AWS Growth: AWS growth accelerated to 28%, with strong performance in advertising and e-commerce, resulting in a stock increase of over 3.5%, while maintaining a full-year capital expenditure of $200 billion, indicating confidence in future growth.
- Microsoft's Cloud Stability: Microsoft reported a 40% growth in cloud services, and despite a stock drop of over 1%, analysts raised price targets, suggesting optimism about its long-term prospects, alongside an increase in capital expenditures.
- Meta's Stock Decline: Meta Platforms saw its stock drop over 8.5% due to an increased capital expenditure forecast, despite solid quarterly results; however, a 5% decline in daily active users raised concerns about its growth outlook.
See More
Eli Lilly Q1 Earnings Exceed Expectations
- Earnings Beat: Eli Lilly reported Q1 earnings of $8.55 per share, significantly surpassing consensus estimates of $6.79, indicating robust profitability and strong market confidence.
- Mounjaro Sales Surge: Mounjaro's global revenue soared 125% to $8.7 billion, with $4.2 billion from the U.S., reflecting strong demand and solidifying Lilly's leadership in the GLP-1 drug market.
- Upgraded Full-Year Outlook: Lilly raised its 2026 revenue guidance to between $82 billion and $85 billion, up from $80 billion to $83 billion, and increased EPS expectations to $35-$37, showcasing management's confidence in future growth.
- Pipeline Expansion through Acquisitions: The recent acquisition of Ajax Therapeutics marks Lilly's sixth deal in 2026, aimed at expanding its oncology pipeline and moving beyond weight-loss drugs, thereby enhancing its competitive edge in the biopharmaceutical sector.
See More
Eli Lilly's Foundayo Pill Launch Shows Strong Initial Demand
- Market Launch Performance: In the initial weeks post-launch, over 20,000 individuals have begun taking Eli Lilly's GLP-1 pill Foundayo, indicating strong market demand, with CEO David Ricks noting that more than 1,000 new users start daily, reflecting growing consumer interest in the new drug.
- FDA Approval and Market Competition: Foundayo received FDA approval earlier this month, becoming the second oral GLP-1 drug after Novo Nordisk's Wegovy, as Eli Lilly strives to maintain its dominance in the GLP-1 market, holding a 60.1% share of the U.S. obesity and diabetes drug market in Q1.
- Sales Growth Comparison: During the first quarter, sales of Lilly's Mounjaro and Zepbound surged by 125% and 80%, respectively, and while Foundayo's sales were not included in this quarter's results, its strong market launch suggests significant future growth potential.
- Brand Building Challenges: Ricks emphasized that as Foundayo is a new drug with limited awareness among doctors and patients, building the brand will take time; despite the current strong demand, he urges the market to exercise patience to allow the company to effectively execute its strategies.
See More
LILLY Q1 ADJUSTED EPS REACHES USD 8.55, BEATING IBES ESTIMATE OF USD 6.66
Economic Adjustments: The report indicates an adjusted earnings per share (EPS) of $8.55, reflecting a positive outlook for the company.
Comparison with Estimates: This adjusted EPS surpasses the estimated EPS of $6.66, suggesting stronger-than-expected financial performance.
See More
Eli Lilly Q1 Earnings Forecast
- Earnings Release Date: Eli Lilly & Co. is set to announce its Q1 earnings on April 30, which is highly anticipated by the market and expected to provide insights into the company's latest developments in drug research and market performance.
- Earnings Per Share Expectation: Analysts forecast that Eli Lilly's Q1 earnings per share will reach $6.79, a significant increase from $3.34 in the same period last year, indicating a robust recovery in drug sales and market demand.
- Stock Price Movement: Despite the optimistic outlook for the earnings report, Eli Lilly's stock fell by 2.6% on Wednesday, likely influenced by overall market sentiment and profit-taking by investors, reflecting short-term market uncertainties.
- Market Reaction Analysis: Analysts maintain a cautiously optimistic view on the upcoming earnings report, anticipating that strong earnings growth will provide funding for future investments and research, thereby enhancing the company's competitive position in the pharmaceutical industry.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
Strong Earnings Reports from Top Tech Giants
- Alphabet's Strong Performance: Alphabet's earnings report exceeded expectations with strong performance in search, subscriptions, and cloud services, leading to an 8% stock increase and reflecting significant returns on AI investments, boosting market confidence.
- Amazon's AWS Growth: AWS growth accelerated to 28%, with strong performance in advertising and e-commerce, resulting in a stock increase of over 3.5%, while maintaining a full-year capital expenditure of $200 billion, indicating confidence in future growth.
- Microsoft's Cloud Stability: Microsoft reported a 40% growth in cloud services, and despite a stock drop of over 1%, analysts raised price targets, suggesting optimism about its long-term prospects, alongside an increase in capital expenditures.
- Meta's Stock Decline: Meta Platforms saw its stock drop over 8.5% due to an increased capital expenditure forecast, despite solid quarterly results; however, a 5% decline in daily active users raised concerns about its growth outlook.
See More
Eli Lilly Q1 Earnings Exceed Expectations
- Earnings Beat: Eli Lilly reported Q1 earnings of $8.55 per share, significantly surpassing consensus estimates of $6.79, indicating robust profitability and strong market confidence.
- Mounjaro Sales Surge: Mounjaro's global revenue soared 125% to $8.7 billion, with $4.2 billion from the U.S., reflecting strong demand and solidifying Lilly's leadership in the GLP-1 drug market.
- Upgraded Full-Year Outlook: Lilly raised its 2026 revenue guidance to between $82 billion and $85 billion, up from $80 billion to $83 billion, and increased EPS expectations to $35-$37, showcasing management's confidence in future growth.
- Pipeline Expansion through Acquisitions: The recent acquisition of Ajax Therapeutics marks Lilly's sixth deal in 2026, aimed at expanding its oncology pipeline and moving beyond weight-loss drugs, thereby enhancing its competitive edge in the biopharmaceutical sector.
See More
Eli Lilly's Foundayo Pill Launch Shows Strong Initial Demand
- Market Launch Performance: In the initial weeks post-launch, over 20,000 individuals have begun taking Eli Lilly's GLP-1 pill Foundayo, indicating strong market demand, with CEO David Ricks noting that more than 1,000 new users start daily, reflecting growing consumer interest in the new drug.
- FDA Approval and Market Competition: Foundayo received FDA approval earlier this month, becoming the second oral GLP-1 drug after Novo Nordisk's Wegovy, as Eli Lilly strives to maintain its dominance in the GLP-1 market, holding a 60.1% share of the U.S. obesity and diabetes drug market in Q1.
- Sales Growth Comparison: During the first quarter, sales of Lilly's Mounjaro and Zepbound surged by 125% and 80%, respectively, and while Foundayo's sales were not included in this quarter's results, its strong market launch suggests significant future growth potential.
- Brand Building Challenges: Ricks emphasized that as Foundayo is a new drug with limited awareness among doctors and patients, building the brand will take time; despite the current strong demand, he urges the market to exercise patience to allow the company to effectively execute its strategies.
See More
